BIO-KOREA
The BIO KOREA Organizing Committee announced it will hold the BIO KOREA 2020 International Convention scheduled for May 18–23 as an online convention instead of an in-person event for this year.
The decision was based on the impact of COVID-19, the safety of the attendees and global health recommendations regarding large, in-person gatherings.
BIO KOREA 2020 Online Convention
- Date: May 18 09:00 to 23 18:00 (KST)
- Point of Access: www.biokorea.org
- Program: Online Business Forum with Partnering, Virtual Exhibition, e-Conference, Invest Fair, Job Fair
Online Business Forum with Partnering
BIO KOREA 2020 Online Convention will focus on the virtual collaboration with its Partnering system allowing attendees to schedule virtual meetings to maximize their business development and licensing potential. International participation continues to grow. Numerous companies from 20+ countries are already joined and expected to showcase their advanced technologies at BIO KOREA 2020.
Definitely expecting to be a place where various kinds of discussion will be held, with Korean companies as not just the companies which are leading bio industry in Korea such as LG Chem Life Science, Samsung Biologics, Celltrion, and Hanmi Pharmaceuticals, etc., also promising SMEs like Organoid Science, YBRAIN, and Amyloid Solution are attending to foster their business. And 24-hour meeting slots will let strengthen your digital network across time zones.
Virtual Exhibition
The new format includes Virtual Exhibition where has set to show the cutting-edge technologies and products of exhibitors in various ways such as Digital Scan, Animation, 360° VR, and so on. 350+ exhibitors, from start-up to the global enterprise, will be at BIO KOREA's virtual exhibition and also there will be COVID-19 Special Zone to introduce South Korea's effective diagnostic tests, high-tech medical technology, and protocols.
e-Conference
The conference of BIO KOREA will also come with the online format under the theme of “A New Paradigm in the Age of Data Science” including expert-level content focused on the most pressing industry topics including COVID-19, Vaccine, Alzheimer’s Disease, Electroceutical, Digital Pathology, Digital Therapeutics, AI (Artificial Intelligence). BIO KOREA 2020’s e-Conference, covering 13 topics with 90+ speakers, will bring the most up-to-date conversations in biopharma to your home office.
Invest Fair
Invest Fair is an event where pharmaceuticals, bio, and healthcare companies that are advancing into the global market and developing new drugs introduce their superior technology and investors to the companies’ vision and strategy. Along with online hosting, it maintains its attendance by impressive lineups of 24 companies such as GC Greencross, Celltrion, Tium BIO, and ABL Bio.
Job Fair
Aiming to place its main objective in recruiting talented individuals amongst undergraduates and postgraduates searching for job vacancies in bio industry, companies participating in Job Fair will share their success tips in various fields. Amid current bleak jobs pictures, about 30 companies are attending with 150+ job openings.
Lastly, BIO KOREA remains committed to amplifying the industry’s efforts to develop solutions for patients. In response to the COVID-19 pandemic, the special sessions dealing with its diagnostic kits, therapeutics and vaccines, also sharing the cooperation among the governments, industries are prepared. Jerom Kim from IVI will deliver the Keynote speech for the COVID-19 special session.
For more information, visit BIO KOREA’s Official Website: www.biokorea.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005997/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom